Skip to content

Effects of Intravenous Lidocaine During Sedation for Colonoscopy.

Investigation of the Effects of Intravenous Lidocaine Infusion During Sedation for Colonoscopy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02784860
Enrollment
40
Registered
2016-05-27
Start date
2016-03-31
Completion date
2016-10-31
Last updated
2018-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy

Keywords

colonoscopy, lidocaine, propofol, sedation

Brief summary

This study assesses the benefits of continuous intravenous lidocaine administration during sedation for colonoscopy. Sedation will consist of propofol infusion titrated to provide adequate working conditions to the gastroenterologist. Patients will be randomly allocated into two groups: lidocaine infusion (bolus of 1.5 mg/kg followed by a continuous infusion of 4 mg/kg/h) or the same volume of placebo (normal saline)

Detailed description

The potential benefits of lidocaine infusion will be tested on: * propofol consumption (primary outcome) * intraoperative respiratory depression * time for patient recovery * postoperative fatigue * postoperative pain * postoperative cognitive dysfunction

Interventions

DRUGLidocaine

Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness

DRUGnormal saline

Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness

Sponsors

University of Liege
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* colonoscopy without gastroscopy

Exclusion criteria

* lidocaine allergy * epilepsy * severe heart rhythm disorders * renal failure with creatinine clearance lower than 30ml/minute

Design outcomes

Primary

MeasureTime frameDescription
Consumption of propofolintraoperativeDose of propofol administered during sedation if measured at the end of it.

Secondary

MeasureTime frameDescription
Time for recoveryintraoperativethe patient is discharged when conscious and able to give his birth date
Quality of working conditions assessed by the gastroenterologistintraoperative
Episodes of oxygen desaturationintraoperativeEpisodes of oxygen desaturation: SpO2 \< 95 and 90%
Postoperative fatigue15 min after sedationFatigue will be assessed on a visual analog scale
Cognitive condition15 minutes after sedationCognitive condition will be evaluated with the MMSE (Minimal Mental State Examination)
Abdominal discomfortintraoperative and 15 minutes laterEvaluation with VAS (visual analog scale) form 0 (no discomfort) to 10 (unbearable Abdominal discomfort assessed on a 0 to 10 visual analog scale

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026